<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401657</url>
  </required_header>
  <id_info>
    <org_study_id>FFR_Ischemia</org_study_id>
    <nct_id>NCT04401657</nct_id>
  </id_info>
  <brief_title>FFR and Inducible Myocardial Ischemia During Adenosine Stress Testing</brief_title>
  <official_title>Relationship Between Fractional Flow Reserve and Inducible Myocardial Ischemia During Adenosine Stress Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single center study involving 150 patients with stable coronary artery&#xD;
      disease undergoing coronary angiography for chest pain evaluation. The relationship between&#xD;
      FFR values and inducible myocardial ischemia at the time of definite ischemia during&#xD;
      adenosine stress testing will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fractional flow reserve (FFR) is commonly used to search for ischemia-producing lesions&#xD;
      during percutaneous coronary intervention (PCI), and its assessment becomes an integral part&#xD;
      to guide PCI when objective evidences of inducible myocardial ischemia are not available. A&#xD;
      transient imbalance between oxygen supply and demand leads to the ischemic cascade, which are&#xD;
      typically accompanied by regional wall motion abnormalities or electrocardiographic changes&#xD;
      as objective evidences of inducible myocardial ischemia.&#xD;
&#xD;
      FFR is a pressure-derived surrogate of coronary flow limitation defined as the ratio of&#xD;
      distal coronary pressure to aortic pressure during maximal hyperemia. FFR has been indirectly&#xD;
      validated against noninvasive stress tests, and large outcome trials support the benefit of&#xD;
      FFR-guided PCI strategy. However, FFR is not a direct measurement of coronary flow, and&#xD;
      myocardial ischemia depends on coronary flow rather than pressure. In fact, an experimental&#xD;
      model shows that myocardial function can be maintained without evidences of myocardial&#xD;
      ischemia despite low FFR. Furthermore, FFR did not predict improvement in symptoms or&#xD;
      exercise performance after PCI, challenging the current threshold of FFR for discriminating&#xD;
      ischemia-producing lesions.&#xD;
&#xD;
      The clinical benefit of FFR-guided PCI is certainly related to relief of inducible myocardial&#xD;
      ischemia. However, there is little information to examine a direct link between FFR values&#xD;
      and documented inducible ischemia at the time of FFR measurement. Therefore, the&#xD;
      investigators investigate the relationship between FFR values and inducible myocardial&#xD;
      ischemia at the time of definite ischemia during adenosine stress testing.&#xD;
&#xD;
      A 12-lead ECG recordings, FFR, and two-dimensional echocardiographic monitoring will be&#xD;
      continued before, during and after adenosine infusion. When new regional wall motion&#xD;
      abnormalities in echocardiography develop, adenosine infusion is ended and echocardiographic&#xD;
      monitoring will be continued until left ventricular wall motion returns to normal. Apical&#xD;
      (two-chamber, four-chamber and five chamber views) and parasternal long-axis and short-axis&#xD;
      views will be recorded for offline analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Definite myocardial ischemia</measure>
    <time_frame>during adenosine stress testing</time_frame>
    <description>Echocardiographic wall motion score index score by 17-segment model or ST segment elevation/depression by 12-lead ECG during adenosine stress testing</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>FFR Measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myocardia ischemia evaluation during adenosine stress testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fractional flow reserve with adenosine stress testing</intervention_name>
    <description>ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.</description>
    <arm_group_label>FFR Measurement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women at least 18 years of age&#xD;
&#xD;
          -  Patients undergoing coronary angiography&#xD;
&#xD;
          -  Moderate to severe stenosis (diameter stenosis equal or more than 50 percent by visual&#xD;
             examination) in one major epicardial coronary artery&#xD;
&#xD;
          -  Normal left ventricular function without regional wall motion abnormality&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to adenosine stress test*&#xD;
&#xD;
          -  ECG abnormalities (bundle branch block, LVH with strain, pacing rhythm, WPW)&#xD;
&#xD;
          -  History of previous myocardial infarction&#xD;
&#xD;
          -  Significant multi-vessel coronary artery disease (diameter stenosis equal or more than&#xD;
             50%)&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Significant valvular heart disease&#xD;
&#xD;
          -  Bronchial asthma or chronic obstructive lung disease&#xD;
&#xD;
          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation&#xD;
             (ALT or AST &gt; 3 times upper limit of normal).&#xD;
&#xD;
          -  Current treatment for the active cancer&#xD;
&#xD;
          -  Expected life expectancy &lt; 1 year&#xD;
&#xD;
          -  Unwillingness or inability to comply with the procedures described in this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheol Whan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Do-Yoon Kang, MD</last_name>
    <phone>82-2-3010-1745</phone>
    <email>kdy1218@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheol Whan Lee, MD, PhD</last_name>
      <email>cheolwlee@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Fractional flow reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

